The treatment of early and advanced HER2-positive breast cancer (BC) patients with trastuzumab (Herceptin®), a humanized monoclonal anti-HER2 antibody, results in both prolonged disease-free and overall survival (DFS, OS). This evidence concerns the gene ERBB2 and breast cancer.